Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 22 (oversold) · MACD below its signal · 3% above its 52-week low
None of the 29 investors followed here reported a position in 145020.KQ in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 145020.KQ trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 20.0 | -2.4 | -10.9 | 5.0 | -1.6 | 6.2 | -11.9 | 8.4 | -28.7 | -6.2 | −26.9% | ||
| 2025 | -15.3 | 33.5 | 5.7 | 9.1 | -9.2 | 16.9 | -13.1 | -6.4 | -4.3 | -13.2 | -12.8 | 0.9 | −17.8% |
| 2024 | 1.7 | 21.0 | 3.9 | 10.7 | -9.7 | 20.9 | 6.3 | 11.0 | -12.1 | 14.0 | -4.8 | 7.9 | +87.8% |
| 2023 | 4.7 | -8.6 | -0.9 | -11.3 | -4.1 | 1.1 | -1.9 | 4.2 | 11.2 | 13.6 | 7.3 | -2.0 | +10.7% |
| 2022 | -11.4 | 7.9 | -5.2 | -9.8 | -0.8 | -15.4 | 27.5 | -8.9 | -16.3 | 9.4 | 2.2 | 18.0 | −12.1% |
| 2021 | 2.7 | -12.2 | 3.8 | 3.4 | 8.9 | 19.3 | -0.3 | -18.3 | -11.3 | 4.6 | -21.3 | 7.9 | −19.5% |
| 2020 | 10.0 | -14.3 | -10.1 | 14.0 | -3.9 | 27.9 | -0.4 | 4.4 | 11.5 | 14.9 | -5.9 | -5.0 | +41.7% |
| 2019 | -12.3 | 4.9 | 7.8 | 9.6 | -3.5 | 5.0 | -10.7 | -1.7 | 4.8 | -5.3 | 4.4 | -11.6 | −11.7% |
| 2018 | 1.0 | -1.3 | 6.3 | -14.9 | -4.4 | -0.1 | -1.0 | -10.2 | -0.2 | -35.9 | 19.9 | 16.0 | −31.8% |
| 2017 | -5.6 | 21.6 | 0.1 | 26.3 | 0.3 | 19.7 | 3.9 | -0.2 | -9.2 | -18.6 | 11.7 | 16.8 | +74.3% |
| 2016 | 23.6 | -8.5 | 24.0 | 9.3 | 11.7 | -6.5 | 10.1 | 19.5 | 1.8 | -19.5 | -19.2 | 15.8 | +61.7% |
| 2015 | — |
No insider transactions reported for 145020.KQ.
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
Buy / hold / sell counts
No recent headlines.